ARS Pharmaceuticals, Inc. (SPRY)
5.89
-0.14
(-2.32%)
USD |
NASDAQ |
Aug 28, 16:00
5.89
0.00 (0.00%)
After-Hours: 20:00
ARS Pharmaceuticals Debt to Equity Ratio : 7.727 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.727 |
| March 31, 2026 | 1.574 |
| December 31, 2025 | 0.8486 |
| September 30, 2025 | 0.6621 |
| June 30, 2025 | 0.0086 |
| March 31, 2025 | 0.0003 |
| December 31, 2024 | 0.0002 |
| September 30, 2024 | 0.0005 |
| June 30, 2024 | 0.0007 |
| March 31, 2024 | 0.001 |
| December 31, 2023 | 0.0012 |
| September 30, 2023 | 0.0014 |
| June 30, 2023 | 0.0015 |
| March 31, 2023 | 0.0017 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0018 |
| September 30, 2022 | 0.0008 |
| June 30, 2022 | 0.0177 |
| March 31, 2022 | 0.0189 |
| December 31, 2021 | 0.2018 |
| September 30, 2021 | 0.0186 |
| June 30, 2021 | 0.0078 |
| March 31, 2021 | 0.0094 |
| December 31, 2020 | 0.0106 |
| September 30, 2020 | 0.0328 |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -2.788 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Passage Bio, Inc. | 0.00 |
| Vertex Pharmaceuticals, Inc. | 0.0977 |
| Capricor Therapeutics, Inc. | 0.3698 |
| Kyntra Bio, Inc. | 0.00 |
| Zentalis Pharmaceuticals, Inc. | 0.2624 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 249.50M |
| Total Liabilities (Quarterly) | 236.98M |
| Shareholders Equity (Quarterly) | 12.51M |
| Current Ratio | 3.475 |
| Net Debt Paydown Yield | -2.43% |